Rivaroxaban, an oral factor Xa inhibitor, may provide a simple, fixed-dose regimen for treating acute deep-vein thrombosis (DVT) and for continued treatment, without the need for laboratory monitoring.
T h e n e w e ng l a n d j o u r na l o f m e dic i n e n engl j med 363;26 nejm.org december 23, 2010 2500 A cute venous thromboembolism (i.e., deep-vein thrombosis [DVT] or pulmonary embolism) is a common disorder with an annual incidence of approximately 1 or 2 cases per 1000 persons in the general population. 1,2 Short-term treatment is effective, with the risk of recurrent disease -the major complication -reduced from an estimated 25% to about 3% during the first 6 to 12 months of therapy. 3 The risk of recurrence remains after treatment ends and can reach 5 to 10% during the first year. 4, 5 Standard treatment for acute venous thromboembolism is limited by the need for parenteral heparin initially, with overlapping administration of a vitamin K antagonist. This presents a challenge to outpatient management, 6 since treatment with a vitamin K antagonist requires laboratory monitoring and dose adjustment and may be complicated by drug and food interactions. After the first year, the annual risk of major bleeding associated with vitamin K antagonists is 1 to 2%. 6 Consequently, the balance between the risks and the benefits of continued therapy remains a subject of debate, despite the high long-term risk of recurrent venous thromboembolism. A simple solution to some of these issues could be administration of an oral anticoagulant that does not require laboratory monitoring yet is effective as a single agent for the treatment of acute venous thromboembolism and for continued treatment.
Rivaroxaban, an orally active, direct factor Xa inhibitor, is effective in the prevention of venous thromboembolism after orthopedic surgery. It does not require laboratory monitoring and has no food interactions and only a few drug interactions. [7] [8] [9] In two dose-finding studies, we established the feasibility of single-agent therapy with rivarox aban in patients with DVT. 10, 11 This led to the EINSTEIN program, consisting of three randomized trials of rivaroxaban: one for the treatment of acute deep-vein thrombosis (the Acute DVT Study), one for the treatment of acute pulmonary embolism (the Acute PE Study), and one for continued treatment in patients who have received treatment for acute deep-vein thrombosis or pulmonary embolism (the Continued Treatment Study). We report the results of the first and third trials; the second trial is ongoing.
Me thods

Study Design and Oversight
The Acute DVT Study was a randomized, openlabel study that compared the efficacy and safety of rivaroxaban with standard therapy consisting of enoxaparin and a vitamin K antagonist in patients with acute, symptomatic DVT. The Continued Treatment Study (EINSTEIN-Extension) was a double-blind study in which patients with confirmed symptomatic DVT or pulmonary embolism who had been treated for 6 or 12 months with a vitamin K antagonist or rivaroxaban were randomly assigned to receive continued treatment with rivaroxaban or placebo. Both trials were sponsored by Bayer Schering Pharma and Ortho-McNeil. The trials were conducted in accordance with the protocol (available with the full text of this article at NEJM.org).
The steering committee had final responsibility for the study designs, clinical protocols, study oversight, and verification and analyses of the data. The protocols were approved by the institutional review board at each center, and written informed consent was obtained from all patients. The data were collected and maintained by the sponsor. All suspected outcome events were classified by a central adjudication committee whose members were unaware of the treatment assignments. An independent data and safety monitoring board periodically reviewed outcomes. The writing committee wrote the manuscript and vouches for the accuracy and completeness of the reported data and analyses and the fidelity of the study to the protocol.
Patients
For the Acute DVT Study, patients were eligible if they were of legal age for consent and had acute, symptomatic, objectively confirmed proximal DVT, without symptomatic pulmonary embolism. Patients were ineligible if they had received therapeutic doses of low-molecular-weight heparin, fondaparinux, or unfractionated heparin for more than 48 hours or if they had received more than a single dose of a vitamin K antagonist before randomization; if they had been treated with thrombectomy, a vena cava filter, or a fibrinolytic agent for the current episode of thrombosis; or if they had any contraindication listed in the labeling of enoxaparin, warfarin, or acenocoumarol.
For the Continued Treatment Study, patients were eligible if they had objectively confirmed, symptomatic DVT or pulmonary embolism and had been treated for 6 to 12 months with acenocoumarol or warfarin (in the EINSTEIN studies or from routine care) or rivaroxaban (in the EINSTEIN studies) and if there was equipoise with respect to the need for continued anticoagulation.
Exclusion criteria for both studies were another indication for a vitamin K antagonist; a creatinine clearance below 30 ml per minute; clinically significant liver disease (e.g., acute hepatitis, chronic active hepatitis, or cirrhosis) or an alanine aminotransferase level that was three times the upper limit of the normal range or higher; bacterial endocarditis; active bleeding or a high risk of bleeding, contraindicating anticoagulant treatment; systolic blood pressure greater than 180 mm Hg or diastolic blood pressure greater than 110 mm Hg; childbearing potential without proper contraceptive measures, pregnancy, or breast-feeding; concomitant use of strong cytochrome P-450 3A4 inhibitors (e.g., human immunodeficiency virus protease inhibitors or systemic ketoconazole) or inducers (e.g., rifampicin, carbamazepine, or phenytoin); participation in another experimental pharmacotherapeutic program within 30 days before screening; and a life expectancy of less than 3 months.
In both studies, patients were randomly assigned to a study group with the use of a computerized voice-response system, with stratification by country. The intended treatment duration was determined by the treating physician.
Treatment Regimens
In the Acute DVT Study, patients assigned to receive oral rivaroxaban were given 15 mg twice daily for the first 3 weeks, followed by 20 mg once daily for the intended 3, 6, or 12 months of treatment. Patients who were assigned to standard therapy received subcutaneous enoxaparin, 1.0 mg per kilogram of body weight twice daily, and either warfarin or acenocoumarol, started within 48 hours after randomization. Enoxaparin was discontinued when the international normalized ratio (INR) was 2.0 or more for 2 consecutive days and the patient had received at least 5 days of enoxaparin treatment. The dose of the vitamin K antagonist was adjusted to maintain an INR of 2.0 to 3.0. The INR was determined at least once per month. The time during which the INR was within the therapeutic range was calculated for each patient from the discontinuation of heparin until the end of treatment, including interruptions. For the Continued Treatment Study, patients were assigned to either rivaroxaban, 20 mg once daily, or matching placebo for the intended treatment duration of 6 or 12 months.
In both studies, the use of nonsteroidal antiinflammatory drugs and antiplatelet agents was discouraged. If indicated, aspirin (up to 100 mg per day), clopidogrel (75 mg per day), or both were allowed.
Surveillance and Follow-up
In both studies, patients were followed for the intended treatment duration and seen at fixed intervals that were identical for the rivaroxaban and comparison groups, at which time a checklist was used to elicit information on symptoms and signs of recurrent venous thromboembolism, bleeding, and adverse events. Patients were instructed to report to the study center immediately if any of these events occurred. In cases of suspected venous thromboembolism, the protocol required objective testing.
Outcome Assessments
For both studies, the primary efficacy outcome was symptomatic, recurrent venous thromboembolism, defined as the composite of DVT or nonfatal or fatal pulmonary embolism, with the use of diagnostic criteria described previously 12 (see the Supplementary Appendix, available at NEJM .org). Death was classified as due to pulmonary embolism, bleeding, or other established causes. Pulmonary embolism was considered the cause of death if there was objective documentation or if death could not be attributed to a documented cause and pulmonary embolism could not be confidently ruled out.
For the Acute DVT Study, the principal safety outcome was clinically relevant bleeding, defined as the composite of major or clinically relevant nonmajor bleeding. For the Continued Treatment Study, the principal safety outcome was major bleeding. Criteria for bleeding were described previously 12 (see the Supplementary Appendix).
Predefined secondary outcomes included allcause mortality, vascular events (acute coronary syndrome, ischemic stroke, transient ischemic at-tack, or systemic embolism), and net clinical benefit (defined as the composite of the primary efficacy outcome or major bleeding). In addition, analyses of the treatment effects and bleeding were performed in prespecified subgroups in both studies. 13
Statistical Analysis
The Acute DVT Study was designed as an eventdriven, noninferiority study. Assuming equal efficacy in the two study groups, a total of 88 events would provide a power of 90% to demonstrate that rivaroxaban is noninferior to standard therapy, with the use of a margin of 2.0 for the upper limit of the 95% confidence interval for the observed hazard ratio at a two-sided alpha level of 0.05. This margin corresponds to maintenance of at least 50% of the proven efficacy of standard therapy. On the basis of a 3% incidence of the primary efficacy outcome, we calculated that we would need a sample of approximately 3000 patients. However, it was specified a priori that the steering committee would decide to stop enrollment when it was estimated that 88 events would be reached. This decision was to be made without knowledge of the outcomes in the treatment groups. When enrollment was discontinued, patients completed their assigned treatment, except for patients in the 12-month stratum who had completed at least 6 months of treatment.
The Continued Treatment Study was an eventdriven, superiority study. Assuming a 70% relative risk reduction with rivaroxaban, a total of 30 events would provide a power of 90% to demonstrate that rivaroxaban is superior to placebo at a two-sided alpha level of 0.05. On the basis of a frequency of the primary outcome of 3.5% for the placebo group, we calculated that we would need a sample of approximately 1300 patients. However, the final sample size was determined as described for the Acute DVT Study, with a minimum treatment duration of 3 months.
For both studies, the primary efficacy analysis was performed on an intention-to-treat basis with the use of a stratified intended-duration Cox proportional-hazards model, adjusted for the presence of a malignant condition at baseline in the Acute DVT Study and pretreatment in the Continued Treatment Study. The safety analyses included all patients who received the assigned study drug. Bleeding events were included in the analy-ses if they occurred during treatment or within 2 days after discontinuation of the study drug.
R e sult s
Study Patients
From March 2007 through September 2009, a total of 3449 patients underwent randomization in the Acute DVT Study (Fig. 1A) Table 1 .
Treatment and Follow-up
For the Acute DVT Study, data on treatment with rivaroxaban or with enoxaparin combined with a vitamin K antagonist (standard therapy), as well as the main reasons for premature discontinuation of treatment, are shown in Table 2 . In the standard-therapy group, the median duration of enoxaparin treatment was 8 days (interquartile range, 6 to 11), and the INR at the end of enoxaparin treatment was 2.0 or higher in 80.8% of patients. Overall, the INR was in the therapeutic range (2.0 to 3.0) for 57.7% of the time, above 3.0 for 16.2% of the time, and below 2.0 for 24.4% of the time. The percentage of time within the therapeutic range varied from 54.1% (month 1) to 66.4% (month 10). Because termination of the study was event-driven, the duration of treatment was shorter than intended for 102 patients (5.9%) in the rivaroxaban group and for 94 patients (5.5%) in the standard-therapy group. In the rivaroxaban group, 15 patients (0.9%) were lost to follow-up as compared with 18 patients (1.0%) in the standard-therapy group.
For the Continued Treatment Study, data on treatment with either rivaroxaban or placebo and the reasons for premature discontinuation of treatment are shown in Table 2 . As a result of eventdriven termination, the duration of treatment was shorter than intended for 156 patients (25.9%) in the rivaroxaban group and for 148 patients (24.9%) in the placebo group. Follow-up for the primary ITT denotes intention to treat, and VKA vitamin K antagonist. efficacy outcome was complete for 601 patients (99.8%) in the rivaroxaban group and for 593 patients (99.8%) in the placebo group.
Clinical Outcomes in the Acute DVT Study
The clinical outcomes are shown in Table 3 . The primary efficacy outcome was suspected in 230 patients in the rivaroxaban group and in 215 patients in the standard-therapy group and was confirmed in 36 and 51 of these patients, respectively. Hence, the primary efficacy outcome occurred in 2.1% of patients in the rivaroxaban group and in 3.0% of patients in the standard-therapy group (hazard ratio, 0.68; 95% confidence interval [CI], 0.44 to 1.04; P<0.001 for noninferiority with a one-sided test, and P = 0.08 for superiority with a two-sided test). The time course of recurrent venous thromboembolism in the two treatment groups is shown in Figure 2A . By day 21 (the end of twice-daily rivaroxaban dosing), the primary efficacy outcome had occurred in 21 patients (1.2%) in the rivaroxaban group and in 29 patients (1.7%) in the standardtherapy group. The results of the on-treatment and per-protocol analyses were similar to those of the intention-to-treat analysis (data not shown).
The principal safety outcome -first major or clinically relevant nonmajor bleeding -occurred in 139 patients (8.1%) given rivaroxaban and in 138 patients (8.1%) given standard therapy (haz-ard ratio with rivaroxaban, 0.97; 95% CI, 0.76 to 1.22; P = 0.77). The time course for the principal safety outcome is shown in Figure 3 .
The outcome of a net clinical benefit occurred in 51 (2.9%) of the patients who received rivaroxaban and in 73 (4.2%) of the patients who received standard therapy (hazard ratio, 0.67; 95% CI, 0.47 to 0.95; P = 0.03). The relative efficacy and safety were consistent across the prespecified subgroups ( Fig. 1 and 2 in the Supplementary Appendix). Vascular events during study treatment occurred Appendix) . The combination of an alanine aminotransferase level exceeding three times the upper limit of the nor-mal range and a bilirubin level exceeding twice the upper limit of the normal range was observed in 2 patients (0.1%) in the rivaroxaban group and 4 patients (0.2%) in the standard-therapy group ( Table 2 in the Supplementary Appendix). 
Clinical Outcomes in the Continued Treatment Study
The clinical outcomes are shown in Table 4 . The primary efficacy outcome occurred in 8 patients (1.3%) in the rivaroxaban group as compared with 42 patients (7.1%) in the placebo group (hazard ratio, 0.18; 95% CI, 0.09 to 0.39; P<0.001, relative risk reduction, 82%). The time course for recurrent venous thromboembolism in the two groups is shown in Figure 2B . The principal safety outcome of major bleeding occurred in 4 patients (0.7%) in the rivaroxaban group and in none of the patients in the placebo group (P = 0.11). The outcome of a net clinical benefit occurred in 12 patients (2.0%) receiving rivaroxaban and in 42 patients (7.1%) receiving placebo (hazard ratio, 0.28; 95% CI, 0.15 to 0.53; P<0.001). The relative efficacy and safety were consistent across the prespecified subgroups ( Fig. 3 and 4 in the Supplementary Appendix). Vascular events occurred in 3 patients in the rivaroxaban group and 4 patients in the placebo group ( Table 3 in the Supplementary Appendix). No patient in either group had the combination of an alanine aminotransferase level exceeding three times the upper limit of the normal range and a bilirubin level exceeding twice the upper limit of the normal range ( 
Discussion
Our studies show that rivaroxaban alone is as effective as standard therapy, with similar safety, for the treatment of acute DVT and that when treatment is continued, rivaroxaban is very effective in preventing recurrences, as compared with placebo, and has an acceptable risk of bleeding. A unique aspect of the Acute DVT Study is the use of rivaroxaban as a single agent, replacing both low-molecular-weight heparin and a vitamin K antagonist in the treatment of DVT. Accordingly, the great majority of patients in the rivaroxaban group either did not receive low-molecular-weight heparin or received a single dose. Nevertheless, efficacy during the first weeks of treatment was similar in the two study groups. A prespecified indicator of net clinical benefit (symptomatic recurrent venous thromboembolism plus major bleeding) favored rivaroxaban. Therefore, the riva roxaban regimen may further facilitate the outpatient management of DVT. The purpose of the Continued Treatment Study was to explore the benefit-to-risk ratio when treatment with rivaroxaban is administered after 6 to 12 months of anticoagulation. At this time point, clinicians must often balance the long-term risks of recurrent venous thromboembolism if anticoagulation is stopped against the burden and risks of ongoing therapy. 6 Rivaroxaban reduced the rate of recurrence by 82% (from 7.1 to 1.3 clinical events), regardless of the type of index event, with a small risk of major hemorrhage (0.7%, with no fatal hemorrhages). Thus, 34 recurrent events were prevented, at the cost of 4 major bleeding events. However, the incidence of clinically relevant nonmajor bleeding was increased from 1.2% in the placebo group to 5.4% with rivaroxaban. These bleeding events were predominantly mucosal, and most patients (81%) resumed or continued the study therapy. Overall, this suggests an acceptable benefit-to-risk profile.
We performed several subgroup analyses. The results for the primary efficacy and safety outcomes were consistent and did not suggest a need for dose modification, regardless of age, sex, weight, and renal function. Furthermore, several important results of both studies warrant attention. Given earlier experience, 14 liver function was carefully monitored, and there was no suggestion of toxicity. In addition, total mortality and rates of cardiovascular events other than venous thromboembolism were low and did not differ significantly between the two groups.
Some methodologic aspects and possible limitations of the studies require comment. First, the Acute DVT Study had an open design and therefore a potential for a diagnostic-suspicion bias; however, the absolute number of patients with a suspected recurrence was slightly higher in the rivaroxaban group, whereas the proportion of patients with recurrences confirmed by the adjudica- tion committee was lower (16%, vs. 25% in the standard-therapy group). This suggests that the open design did not influence the results. Second, it is important that therapy in the comparison group in the Acute DVT Study was administered to a high standard; this is indicated by the good quality of both initial low-molecular-weight hep-arin therapy and the switch to a vitamin K antagonist and the overall 58% of time in the therapeutic range with vitamin K antagonists, which is similar to the results of other recent thrombosis studies. 12, 15 Third, the internal validity of both studies is reinforced by the low rate of loss to follow-up. Fourth, patient selection bias is unlikely: in the Acute DVT Study, the control group had a recurrence rate of 3%, which is consistent with the rates in recent studies, 12, 15 as is the 7.1% recurrence rate with placebo. 16, 17 Fifth, the characteristics of the patients in each study were similar to those in other studies, which supports the generalizability of our findings. 12, [15] [16] [17] Sixth, the use of placebo in the Continued Treatment Study could be criticized; however, the entry criteria specified that there should be clinical equipoise regarding the cessation or continuation of anticoagulant therapy, and patients had completed 6 to 12 months of treatment. Finally, the proportion of patients with active cancer at the time of enrollment in the Acute DVT Study was moderate (7% in both groups). Although both the relative efficacy and safety of rivaroxaban were similar to those of standard therapy in these patients, more data are needed for this subgroup.
In conclusion, oral rivaroxaban, at a dose of 15 mg twice daily for the first 3 weeks, followed by 20 mg once daily thereafter, without the need for laboratory monitoring, may provide an effective, safe, single-drug approach to the initial and continued treatment of venous thrombosis.
